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induced anti-inflammatory effects by reduction of aortic 
mRNA expression of IL-6, TNF-alpha and TGF-beta.  Conclu-
sion: HRR by ivabradine improves vascular compliance in 
ApoE – / – mice. Contributing mechanisms include downregu-
lation of the AT1 receptor, attenuation of oxidative stress and 
modulation of inflammatory cytokine expression. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Epidemiological evidence suggests that resting heart 
rate is associated with cardiovascular morbidity and 
mortality  [1] . Subsequently increased resting heart rate 
has emerged as a risk marker and target for primary and 
secondary prevention. Experimental and clinical data 
suggest that sustained elevation of resting heart rate con-
tributes to the pathogenesis of vascular disease. The un-
derlying mechanisms are only partially understood and 
appear to involve cellular signalling events leading to vas-
cular oxidative stress, endothelial dysfunction and accel-
eration of atherogenesis  [2–5] .
 The large central arteries play an important physiolog-
ical role in buffering the cyclic changes in pressure result-
ing from intermittent ejection of blood. Over a person’s 
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 Abstract 
 Background: Impaired vascular compliance is associated 
with cardiovascular mortality. The effects of heart rate on 
vascular compliance are unclear. Therefore, we characterized 
effects of heart rate reduction (HRR) by I( f  ) current in hibition 
on aortic compliance and underlying molecular mechanisms 
in apolipoprotein E-deficient (ApoE – / – ) mice.  Methods: 
ApoE – / – mice fed a high-cholesterol diet and wild-type (WT) 
mice were treated with ivabradine (20 mg/kg/d) or vehicle for 
6 weeks. Compliance of the ascending aorta was evaluated 
by MRI.  Results: Ivabradine reduced heart rate by 113  8 31 
bpm (  19%) in WT mice and by 133  8 6 bpm (  23%) in
ApoE – / – mice. Compared to WT controls, ApoE – / – mice exhib-
ited reduced distensibility and circumferential strain. HRR by 
ivabradine increased distensibility and circumferential strain 
in ApoE – / – mice but did not affect both parameters in WT 
mice. Ivabradine reduced aortic protein and mRNA expres-
sion of the angiotensin II type 1 (AT1) receptor and reduced 
rac1-GTPase activity in ApoE – / – mice. Moreover, membrane 
translocation of p47 phox was inhibited. In ApoE – / – mice, HRR 
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lifetime they adapt to mechanical demands and remodel 
by changing their geometry, structure and elastic proper-
ties. Compliance, defined as change in volume for a given 
change in distending pressure, decreases steadily with 
vascular aging  [6] . Reduced compliance alters arterial 
pressure and flow dynamics and impacts cardiac perfor-
mance and coronary perfusion. Aortic stiffness, namely 
the inverse of compliance, predicts cardiovascular mor-
bidity and mortality in patients with cardiovascular dis-
ease  [7] . Molecular mechanisms contributing to arterial 
stiffness may involve activation of the renin-angiotensin-
aldosterone-system (RAAS), increased vascular oxidative 
stress and expression of inflammatory molecules  [8, 9] .
 As an integral component of pulsatile mechanical 
stress, heart rate may affect the mechanical properties of 
large arteries resulting in structural alterations and ag-
gravation of atherosclerotic disease  [10] . In experimental 
studies, accelerated heart rate was shown to affect visco-
elastic properties of the vascular wall resulting in the re-
duction of arterial compliance  [11–13] . Apolipoprotein E 
knockout (ApoE – / – ) mice develop atherosclerotic lesions 
and exhibit hemodynamic alterations in indexes of vas-
cular resistance and compliance  [14] . As direct measure-
ments of aortic compliance, the distensibility (given as 
the relative change in vessel cross-sectional area over 
pulse pressure) and the circumferential cyclic strain 
(which implies the ratio of the systolic and the diastolic 
vessel circumferences) can be determined by MRI. 
 The I( f  ) current inhibitor ivabradine reduces heart 
rate without influencing left ventricular contractile func-
tion and blood pressure and may be used as a tool to study 
the effects of heart rate on vascular biology  [15] . This 
study was therefore undertaken to test the hypothesis 
that selective heart rate reduction (HRR) induced by iva-
bradine may affect aortic compliance as well as to char-
acterize underlying molecular mechanisms.
 Methods 
 Animals, Heart Rate and Blood Pressure 
 Animal experiments were conducted in accordance with in-
stitutional guidelines and the German animal protection law. 
Male ApoE –/– and C57/Bl6 [wild-type (WT)] mice (Charles River 
Laboratories, Sulzfeld, Germany) were used for this study. The 
animals were maintained in a 22   °   C room with a 12-hour light/
dark cycle and received drinking water and food ad libitum. 
ApoE – / – mice were fed a high-fat, cholesterol-rich diet for 6 weeks 
starting at 12 weeks of age. WT mice received regular chow. At the 
same age, animals were randomized to oral ivabradine (ivabra-
dine hydrochloride, S 16257–2, Servier, France) (20 mg/kg body 
weight) or vehicle treatment via drinking water. Six weeks after 
treatment initiation, heart rate and blood pressure were measured 
by a computerized tail-cuff system as described  [2] . 
 Magnetic Resonance Imaging 
 After 6 weeks, drug treatment was terminated and paused for 
3 more days to adjust heart rates. Mice were subjected to MRI us-
ing a horizontal bore 9.4 Tesla animal scanner (Bruker BioSpin 
94/20, Ettlingen, Germany). The MR system was run with ParaVi-
sion 5.1 including the IntraGate/software for the sequence acqui-
sition and reconstruction. All experiments were performed during 
general anesthesia using a mixture of 1.5–2% isoflurane and 100% 
oxygen with a flow rate of 1.5 l/min. Mice were positioned prone 
in a dedicated cradle including the 4-element (2  ! 2) phased-array 
surface coil (Bruker BioSpin). A water-heated blanket was fixed on 
the body of the animals to prevent hypothermia and core temper-
ature was measured using a rectal sensor. ECG signal was derived 
from external electrodes attached to the front paws and a pressure 
transducer attached to the abdominal wall allowed for monitoring 
of the respiration rate. We acquired a double-gated bright-blood 
cine sequence (Intragate Flash, TR/TE = 8.9/2.1 ms, flip angle = 
10°, field of view = 2  ! 2 cm, matrix = 384  ! 384 and slice thick-
ness = 1 mm) located perpendicular to the ascending aorta beyond 
the sinus valsalvae at the level of the left pulmonary artery. A total 
of 25 cine frames of the acquired raw data were reconstructed, dis-
playing one cardiac cycle. Quantitative evaluation of the data in-
cluded assessment of the cross-sectional vessel lumen at end-sys-
tole and end-diastole at the level of the left pulmonary artery. For 
quantitative evaluation, the acquired image data was transferred 
to an external workstation and analyzed by a single blinded ob-
server using image evaluation software (OsiriX, Apple Inc., USA). 
Aortic distensibility was calculated using the formula: distensibil-
ity = (end-systolic aortic area – end-diastolic aortic area)/(end-di-
astolic aortic area  ! pulse pressure)  [16] . Circumferential cyclic 
strain was calculated using the formula: circumferential cyclic 
strain = 0.5  ! (C S 2 /C D 2 -1) where C S is the systolic circumference 
and C D is the diastolic circumference  [17] .
 Histomorphometry 
 Aortic wall thickness and medial cross-sectional area (MCSA) 
were assessed in samples of the thoracic aorta of WT and ApoE – / – 
mice after staining with hematoxylin-eosin. Mice were eutha-
nized with an overdose of ketamine/xylazine and perfusion fixed 
in 4% formalin. Aortic segments were longitudinally embedded 
in paraffin and 3 successive sagittal sections (3   m) were stained 
with hematoxylin-eosin. Wall thickness and MCSA were deter-
mined by computer-directed image analysis (NIS-Elements, BR 
3.2, Nikon instruments, USA).
 Vascular Gene Expression Analysis 
 RNA from aortic homogenates was isolated with RNA-clean. 
One microgram of the isolated total RNA was reverse transcribed 
using random primers and MMLV reverse transcriptase for 60 
min at 42  °  C and 10 min at 75  °  C. Aortic mRNA expression of an-
giotensin II type 1 (AT1) receptor was quantified with the Taq-
Man PCR system (Abi Prism 7700 Sequence Detection System, PE 
Biosystems) using TaqMan probe Mm00616371_m1 provided by 
Applied Biosystems. Real-time RT-PCR using SYBR Green (Ap-
plied Biosystems, Darmstadt, Germany) was performed for 
mm18SrRNA (forward 5  -TCAACACGGGAAACCTCAC-3  , re-
verse 5  -ACCAGACAAATCGCTCCAC-3  ), mmIL6 (forward 5  -
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TCCTACCCCAATTTCCAATG-3  , reverse 5  -ACCACAGTG-
AGGAATGTCCA-3  ), mmTNF-alpha (forward 5  -GATTATGG-
CTCAGGGTCCAA-3  , reverse 5  - CTCCCTTTGCAGAACTC-
AGG-3  ) and mmTGF-beta (forward 5  -AGCCCGAAGCGG-
ACTACTAT-3  , reverse 5  -TCCACATGTTGCTCCACACT-3  ). 
Expression was normalized to 18S ribosomal RNA.
 Western Blotting 
 Immunoblotting for AT1 receptor (ab47162, Abcam, UK), 
p47 phox (sc-14015, Santa Cruz, USA), Rac1 (05–389, Millipore, 
USA) and GAPDH (sc-32233, Santa Cruz) to control for equal 
protein loading was performed as described  [18] . Rac1 GST-PAK 
pull down assays to determine Rac1 activity and membrane prep-
arations were performed as described  [18] .
 Angiotensin II Concentration and Angiotensin-Converting 
Enzyme Activity 
 Serum angiotensin II concentration was determined by ELISA 
using Assay Max from Assay Pro (USA). Serum angiotensin-con-
verting enzyme (ACE) activity was determined by a colorimetric 
test using an enzymatic assay kit from Bühlmann (Switzerland).
 Statistical Analysis 
 Results are presented as mean  8 SEM. The unpaired Student 
t test and ANOVA for multiple comparisons were employed where 
applicable. Post hoc comparisons were performed with the New-
man-Keuls test. Values of p  ! 0.05 were considered statistically 
significant.
 Results 
 Heart Rate Reduction by Ivabradine 
 Twelve-week-old WT and ApoE – / –    mice were random-
ized to ivabradine (20 mg/kg body weight) or vehicle for 
6 weeks.  Table 1 shows mean heart rates, systolic and di-
astolic blood pressures after 6 weeks of treatment. Ivabra-
dine decreased heart rate by 19% (113  8 31 bpm) in WT 
and 23% (133  8 6 bpm) in ApoE – / – mice. Systolic, dia-
stolic and mean arterial blood pressures were not altered 
significantly, whereas pulse pressure and the pressure 
rate product were reduced in the group of ivabradine-
treated ApoE – / – mice.
 Heart Rate Reduction Improves Aortic Distensibility 
and Circumferential Cyclic Strain 
 As direct measurements of aortic compliance, the dis-
tensibility and the circumferential cyclic strain were de-
termined by MRI. Drug treatment was discontinued 3 
days in advance to adjust heart rates. In contrast to age-
matched WT controls, ApoE – / – mice exhibited reduced 
distensibility (0.029  8 0.002 10 –3 mm Hg –1 vs. 0.015  8 
0.001 10 –3 mm Hg –1 , p  ! 0.01) ( fig. 1 g). HRR by ivabradine 
markedly attenuated the decrease of distensibility in 
ApoE – / – mice to 0.024  8 0.002 10 –3 mm Hg –1 (p  !  0.01) 
( fig. 1 e–g). Circumferential cyclic strain was markedly re-
duced in ApoE – / – mice compared to WT controls (33.8  8 
3% vs. 19.5  8 1%, p  ! 0.01). Treatment with ivabradine 
increased circumferential strain compared to untreated 
ApoE – / – mice (28.1  8 3%, p  ! 0.01) ( fig. 1 h). In contrast 
to ApoE – / – mice, HRR did not affect distensibility and 
circumferential cyclic strain in WT mice.
 To rule out changes in vascular wall morphology that 
could account for the increase in aortic compliance in-
duced by HRR wall thickness and MCSA were assessed 
in samples of the thoracic aorta after staining with hema-
toxylin-eosin. Wall thickness and MCSA did not differ 
between vehicle-treated WT and ApoE – / – mice [wall 
thickness (  m): WT 34.1  8 1 vs. ApoE – / – 34.9  8 2 and 
Table 1. E ffects of treatment with ivabradine (20 mg/kg/day) or vehicle for 6 weeks on heart rate, blood pressure, 
pulse pressure and the pressure rate product
WT
vehicle
WT
Iva
ApoE
vehicle
ApoE
Iva
Heart rate, bpm 606825 493830a 583820 44983b
SBP, mm Hg 11783 12184 11485 11181
DBP, mm Hg 10183 10786 8785 9181
MAP, mm Hg 10683 10685 9685 9781
PP, mm Hg 1682 1482 2883c 2083d
PP ! HR,
103 ! mm Hg ! bpm 9.882 7.480.8 16.182e 9.180.1f
D ata appear as mean 8 SEM. Per group: WT n = 5, ApoE–/– n = 10. DBP = Diastolic blood pressure; MAP 
= middle arterial pressure; PP = pulse pressure; SBP = systolic blood pressure.
a p < 0.05 vs. WT vehicle. b p < 0.001 vs. ApoE–/– vehicle. c p < 0.05 vs. WT vehicle. d p < 0.05 vs. ApoE–/– ve-
hicle. e p < 0.05 vs. WT vehicle. f p < 0.01 vs. ApoE–/– vehicle.
 HRR Improves Aortic Compliance J Vasc Res 2012;49:432–440 435
MCSA ( ! 10 3   m 2 ): WT 78.6  8 2 vs. ApoE – / – 79.5  8 4]. 
Neither parameter was affected by HRR in WT or
ApoE – / – mice [wall thickness (  m): WT 33.2  8 2 vs. 
ApoE – / – 35.9  8 4 and MCSA ( ! 10 3   m 2 ): 76.6  8 3 vs. 
81.4  8 3] ( fig. 1 i–l).
 Ivabradine Reduces Aortic AT1 Receptor Expression 
 To address the effects of HRR on the RAAS serum ac-
tivity of the ACE and concentration of angiotensin II 
(ANG II) was investigated in WT and in ApoE – / – mice. 
In addition, mRNA and protein expression of the AT1 
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 Fig. 1. Effect of HRR on aortic distensibil-
ity and circumferential cyclic strain.
 a MRI through the mouse heart and as-
cending aorta. The line indicates the posi-
tion of the acquired sequence for the as-
sessment of cross-sectional vessel area 
measurement.  b Representative cine se-
quence perpendicular to the ascending 
aorta at the level of the pulmonary trunk. 
 c–f Representative cross sections of end-
diastolic (ED) and end-systolic (ES) aortic 
vessel area in vehicle- ( c ,  d ) and ivabra-
dine-treated ( e ,  f ) ApoE – / – mice. Quantifi-
cation of aortic distensibility ( g ) and cir-
cumferential cyclic strain ( h ).  i–l Repre-
sentative aortic sections of WT and 
ApoE – / – mice (n = 5 per group) stained 
with hematoxylin-eosin (mean  8 SEM; 
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receptor was investigated in aortic homogenates. HRR 
with ivabradine did not alter angiotensin II concentra-
tion or ACE activity in the serum of ApoE – / – mice ( fig. 
2 a, b). Western blotting and TaqMan PCR demonstrated 
markedly increased expressions of the AT1 receptor in 
the thoracic aorta of ApoE – / – mice compared to WT con-
trols which were significantly attenuated by ivabradine. 
In detail, ivabradine decreased protein expression to 453 
 8 91% (vehicle 1420  8 320%, p  !  0.05) ( fig. 2 c, d) and 
mRNA expression to 191  8 22% (vehicle 274  8 30%,
p  ! 0.05) ( fig. 2 e).
 Heart Rate Reduction Attenuates Rac1 Activity and 
Membrane Translocation of p47 phox 
 A major source of superoxide radicals in the vascular 
wall, the NADPH oxidase, was shown to be affected by 
heart rate  [2] . The activity of the small GTP-binding 
protein rac1 and the membrane translocation of the cy-
tosolic regulatory subunit p47 phox are prerequisites for 
NADPH oxidase activation and subsequent reactive ox-
ygen species (ROS) production. Protein expressions of 
rac1 and p47 phox were upregulated in ApoE – / – mice 
compared to WT controls ( fig. 3 a), but were not affected 
by ivabradine. Rac1 GST-PAK pull-down assays were 
performed to quantify rac1 activity in aortic homoge-
nates. HRR with ivabradine decreased rac1 activity to 41 
 8 3% of vehicle-treated ApoE – / – mice (p  ! 0.05) ( fig. 3 
b, c). Moreover, ivabradine decreased membrane trans-
location of p47 phox to 39  8 5% in ApoE – / – mice ( fig. 3 b, 
d) (p  ! 0.05).
 Inflammatory Cytokines and TGF-Beta Are 
Modulated by Ivabradine 
 Inflammation plays a central role in the pathogenesis 
of atherosclerosis and may contribute to the stiffening of 
large arteries via changes in the composition of the arte-
rial wall  [19] . We previously characterized heart-rate-de-
pendent anti-inflammatory effects in ApoE – / – mice  [2, 
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20] and characterized the aortic expression of TNF-al-
pha, IL-6 and TGF-beta consecutively.
 Real-time RT-PCR demonstrated markedly increased 
expressions of TNF-alpha, IL-6 and TGF-beta in ApoE – / – 
mice compared to WT controls (p  ! 0.05). HRR attenu-
ated the expression of inflammatory gene expression in 
the thoracic aorta of ApoE –/– mice after 6 weeks of treat-
ment with ivabradine. In detail, ivabradine decreased the 
expression of TNF-alpha to 90  8 9% (ApoE – / – vehicle 
171  8 30%, p  ! 0.05), IL-6 to 263  8 35% (ApoE – / – ve-
hicle 667  8 140%, p  ! 0.05) and TGF-beta to 134  8 31% 
(ApoE – / – vehicle 421  8 109%, p  ! 0.05) of vehicle ( fig. 
4 a-c).
 Discussion 
 The data show that the vascular phenotype of hyper-
lipidemic ApoE – / – mice is characterized by impairment 
of central vascular distensibility and circumferential cy-
clic strain. Sustained HRR induced by the I( f  ) current 
inhibitor ivabradine improves aortic distensibility and 
strain and preserves aortic compliance. Ivabradine re-
duced aortic expression of the AT1 receptor, decreased 
Rac1 activity and prevented membrane translocation of 
p47 phox . Moreover, the expression of inflammatory cyto-
kines and TGF-beta was markedly reduced.
 Evidence for a causal association between increased 
resting heart rate and arterial stiffness derives from 
cross-sectional studies demonstrating an association 
between heart rate and increased pulse wave velocities 
 [13, 21] . Direct effects of accelerated heart rate on arte-
rial compliance have been investigated in several exper-
imental settings. In rats and humans, progressive in-
creases in heart rate induced by atrial pacing led to stiff-
ening of elastic- and muscle-type arteries  [11, 12, 22] . 
The inverse – the effect of HRR – was tested in rodents 
using ivabradine. In dyslipidemic mice and in rats, HRR 
by ivabradine or metoprolol reduced vascular stiffness 
 [23, 24] . The data here characterized central aortic elas-
ticity in ApoE – / – mice, an animal model that has been 
well characterized regarding lipid-induced alterations 
and which is affected by enhanced vascular stiffness in 
the absence of elevated blood pressure  [14] . High choles-
terol-fed ApoE – / – mice exhibit a markedly reduced aor-
tic compliance compared to their WT littermates. Sus-
tained HRR by ivabradine attenuates a decrement of 
distensibility and restores circumferential cyclic strain. 
This effect is accompanied by a reduction in arterial 
pulse pressure which has been shown to be closely re-
lated to vascular wall stiffness  [25] . Ivabradine has no 
negative effect on the distensibility of healthy arteries in 
WT mice.
 Mechanistically, the elastic behavior of the thoracic 
aorta is determined by structural components of the arte-
rial wall, largely by the medial layer. Albaladejo et al.  [24] 
 tested the effects of HRR with ivabradine on the mor-
phology of the thoracic aorta of spontaneously hyperten-
sive rats. Ivabradine mediated antihypertrophic effects in 
terms of regression of media thickness and MCSA. How-
ever, in this study, HRR with ivabradine exerted no effect 
on MCSA or wall thickness in WT or in ApoE – / – mice. 
Basically, this finding may be due to the atherosclerotic 
phenotype which is not primarily focused on alterations 
of the medial layer in contrast to the hypertensive vascu-
lar phenotype.
 Beyond structural properties, vascular tone and com-
pliance are significantly influenced by endothelial func-
tion. Several studies suggest that endothelial dysfunction 
and reduced nitric oxide bioavailability contribute to ar-
terial stiffening  [26–28] . Recently, HRR by I( f  ) current 
inhibition was shown to improve endothelial-dependent 
vasorelaxation in different types of mice and disease 
models, and ivabradine was characterized as an effective 
tool to conserve endothelial function  [2–5, 23] . Since 
heart rates were matched before MRI, the observed ef-
fects reflect chronic alterations. We thus suggest that the 
primary mechanism by which ivabradine restores vascu-
lar compliance is an improvement of endothelial-depen-
dent vasorelaxation.
 Clinical and experimental evidence links the RAAS to 
vascular stiffness. The enhanced activity of different 
RAAS components was shown to contribute to reduced 
vascular compliance via a multitude of vascular altera-
tions  [8] . In this study in ApoE – / – mice, expression of the 
AT1 receptor, the predominant mediator of maladaptive 
RAAS effects, was markedly downregulated on mRNA 
and protein levels by selective HRR. Besides a relevant 
number of classic agonists known to regulate RAAS ac-
tivity and AT1 receptor expression in vascular cells, he-
modynamic and mechanical forces may interact with the 
RAAS or may even stimulate its activity  [29–31] . Cyclic 
mechanical stress, the transmural force imposed on the 
vessel wall, was shown to increase AT1 receptor activity 
and expression independently of angiotensin II in vascu-
lar smooth-muscle cells and cardiomyocytes  [30, 31] . 
Bolduc et al.  [23] investigated the effect of heart rate on 
carotid artery stiffness in dyslipidemic mice and demon-
strated that heart-rate-associated mechanical stress di-
rectly contributes to carotid artery stiffening. In turn, the 
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reduction of mechanical stress via HRR with ivabradine 
or metoprolol reduced carotid stiffness. In view of these 
findings, though not directly evaluated, our data provide 
evidence for a functional link between mechanical wall 
stress and AT1 receptor expression in the thoracic aorta 
of ApoE – / – mice.
 A hemodynamic force that might be affected by heart 
rate, although not clarified experimentally, is wall shear 
stress. Lehoux et al. [29] detected a pronounced expres-
sion of the AT1 receptor in the inner atheroprone region 
of the aortic arch characterized by low wall shear stress. 
Moreover, they showed that laminar shear stress down-
regulates AT1 receptor expression in human umbilical-
vein endothelial cells. Evidence for a potential link be-
tween shear stress and heart rate originates from in vitro 
studies suggesting that shear waveform, and particularly 
shear frequency, can determine endothelial-cell gene ex-
pression profiles. A ‘physiological’ shear frequency of 1 
Hz (1/s   60/min) repressed inflammatory transcripts 
and induced several atheroprotective transcripts in vas-
cular endothelial cells  [32] . However, since substantial ex-
perimental evidence for a connection between shear 
stress and heart rate is still lacking, one may speculate 
that increased heart rate promotes disturbed (e.g. oscilla-
tory) flow that may be ‘redirected’ to more laminar flow 
by HRR. A hypothesis that remains to be evaluated by 
future research.
 Studies on isolated vascular endothelial and smooth-
muscle cells as well as in vivo experiments showed that 
pulsatile mechanical signals are capable of inducing the 
release of ROS  [33] . A recently published study linked ox-
idative stress to impaired arterial elasticity in healthy 
subjects without confounding risk factors  [34] . Previous 
experiments by our group demonstrated that NADPH 
oxidase activity was downregulated in the aorta of iv-
abradine-treated ApoE – / – mice  [2] . Consequently, in this 
study, we tested for effects on NADPH subunits, Rac1 and 
p47 phox which are essential for NADPH-associated ROS 
release. HRR negatively affected rac1 activity and re-
duced p47 phox membrane translocation. These findings 
contribute to the established antioxidative effects of iv-
abradine on the vasculature and extend the mechanisms 
by which increased heart rate mediates atheroprone ef-
fects.
 Biomarkers of inflammation like CRP, interleukin-6 
and TNF-alpha have been associated positively with mea-
sures of arterial stiffness in studies in apparently healthy 
individuals and in groups of patients with cardiovascular 
disease  [35] . Inflammatory molecules are involved in sev-
eral stages of vascular stiffening  [9] . In vascular cells, cy-
clic stretch at pathological amplitudes induced distinct 
expression patterns of genes involved in inflammatory 
responses  [36] . Here we describe a reduction of inflam-
matory cytokine expression by HRR. These anti-inflam-
matory effects support our earlier findings of a potent 
downregulation of inflammatory cytokines by ivabra-
dine in ApoE – / – mice  [2, 20] . TGF-beta acts as a central 
player in the development of fibrosis in chronic inflam-
matory conditions  [9] . Corresponding to IL-6 and TNF-
alpha, mRNA expression of TGF-beta was reduced by iv-
abradine, confirming a robust effect of reduced heart rate 
on the signaling events leading to vascular stiffness.
 In conclusion, chronic HRR induced by I( f  ) current 
inhibition restores aortic compliance in a mouse model 
of lipid-induced atherosclerosis. Signaling associated 
with arterial stiffening involves the combined influences 
of several distinctive pathways and external risk factors. 
Here we show positive effects on the RAAS, oxidative 
stress and inflammation. HRR reduces AT1 receptor ex-
pression, attenuates vascular oxidative stress via reduced 
rac1 activity and p47 phox membrane translocation and 
modulates vascular inflammatory cytokine expression. 
As previous experiments ruled out direct effects of iva-
bradine on cultured vascular cells and aortic ring prepa-
rations  [2, 20] , sustained HRR and potentially associated 
vascular mechanical modifications are likely the primary 
mechanisms at work. Although a causative association 
between the expression of molecular targets and aortic 
stiffness could not be verified, the results provide evi-
dence for a strong functional link between heart rate and 
vascular stiffening in the thoracic aorta of ApoE – / – mice 
that may be reduced by ivabradine, a hypothesis that is 
still to be tested in a clinical trial.
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